Degeneration of macula and posterior pole
MONDO:0002175Also known as: degeneration of macula and posterior pole of retina
366 clinical trials for this condition and its sub-types, 0 tagged with Degeneration of macula and posterior pole itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Degeneration of macula and posterior pole
-
Age-related macular degeneration 190 trials · 334 incl. sub-types
15 sub-types
- Wet macular degeneration 159 trials
- Dry age related macular degeneration 91 trials
- Age related macular degeneration 1 0 trials
- Age related macular degeneration 10 0 trials
- Age related macular degeneration 11 0 trials
- Age related macular degeneration 12 0 trials
- Age related macular degeneration 14 0 trials
- Age related macular degeneration 2 0 trials
- Age related macular degeneration 4 0 trials
- Age related macular degeneration 6 0 trials
- Age related macular degeneration 7 0 trials
- Age related macular degeneration 8 0 trials
- Age related macular degeneration 9 0 trials
- Macular degeneration, age-related, 3 0 trials
- Macular dystrophy with central cone involvement 0 trials
-
Preretinal fibrosis 21 trials
-
Toxic maculopathy 2 trials
-
Retinal drusen 0 trials · 2 incl. sub-types
3 sub-types
- Reticular pseudodrusen 2 trials
- Doyne honeycomb retinal dystrophy 0 trials
- Basal laminar drusen 0 trials
-
Hole retinal cyst 1 trial
-
Cystoid macular retinal degeneration 0 trials
-
New eye injection targets Blindness-Causing lesions
Disease control Stopped earlyThis early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control Stopped earlyThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise but trial halted early
Disease control Stopped earlyThis study tested a single injection of GT005, a gene therapy, in 255 people with geographic atrophy from dry age-related macular degeneration. The goal was to see if it could slow the growth of blind spots in the eye. The trial was terminated early, so we have less data than hop…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene injection targets dry AMD
Disease control Stopped earlyThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Phase 1/2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
VR headsets tested as a possible treatment for blindness
Disease control Stopped earlyThis study tested whether using a virtual reality headset for one-hour sessions could help regenerate damaged optic nerves and improve vision in people with glaucoma or other retinal diseases. The idea came from promising results in rodents. However, the trial was terminated earl…
Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Eye drug trial halted: could danicopan still slow blind spots?
Disease control Stopped earlyThis Phase 2 study tested an oral drug called danicopan in 365 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants took different doses of danicopan or a placebo for up to 104 weeks to see if it could slow…
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:21 UTC
-
Corn could be key to saving your eyesight
Prevention Stopped earlyThis study looked at whether eating corn rich in zeaxanthin (a natural pigment) could increase the density of the macular pigment in the eye, which may help prevent age-related macular degeneration (AMD), a leading cause of blindness. Nine healthy volunteers aged 20-35 ate a dail…
Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Can genetics predict the worsening of geographic atrophy?
Knowledge-focused Stopped earlyThis study follows people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots, to see how their vision changes over time. Researchers will measure visual function, such as reading speed and sensitivity to light, and track the growth …
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
New eye camera could spot hidden signs of blindness
Knowledge-focused Stopped earlyThis study tested a new, non-invasive eye imaging method called hyperspectral imaging. It takes pictures of the back of the eye using many different colors of light to find details not visible with standard cameras. About 679 adults with healthy eyes or eye diseases like diabetic…
Sponsor: Center for Eye Research Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New score could help eye surgeons predict who sees best after surgery
Knowledge-focused Stopped earlyThis study aimed to validate a scoring system that predicts whether patients will have good vision one year after combined cataract and epiretinal membrane surgery. The score uses factors like age, symptom duration, and initial vision. Researchers planned to enroll 164 adults age…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC